Thank you for registering with Pulmonary Fibrosis New’s Clinical Trial Registry.
We will inform you of new clinical trials as information becomes available.
In the meantime, feel free to access these other PF-related resources:
Ofev News:
- Ofev Benefits IPF Patients Irrespective of Initial Prognosis, Trials’ Data Show
- Despite Benefits, Many IPF Patients Switching from Esbriet to Ofev Stop Treatment, Possibly Due to Low BMI, Study Says
- IPF Patients Live Longer on Ofev Compared with Placebo, Analysis Suggests
- Secondary Insurance Coverage Boosts Adherence to Treatment with Ofev, Esbriet, Study Finds
- Ofev Affects Cell Cycle Genes in IPF Fibroblasts, Study Finds
- Algernon Plans to Test Its Lead Anti-fibrotic Compound in Animal Study of IPF
- Real-world Use of Esbriet and Ofev Supports Their Safety and Tolerability, Study Says
IPF News:
- Genetic Variants of MUC5AC Gene May Be a Risk Factor for IPF, Study Suggests
- Repeated Lung Cancer Surgery in IPF Patients May Worsen Outcomes
- Online ‘Personal Health’ Campaign Aims to Educate and Empower People with Lung Diseases
- Breathing Easier on the Canadian West Coast
- PF Brain Fog Struggles and Solutions
- Aloperine May Protect Against Pulmonary Fibrosis in Mouse Model, Study Suggests
- Yankees’ Bernie Williams Talks About His Father’s Journey With IPF
Esbriet News:
- Esbriet Helps Halt Breathlessness Symptoms in Severe IPF, Analysis of Multiple Trials Shows
- Despite Benefits, Many IPF Patients Switching from Esbriet to Ofev Stop Treatment, Possibly Due to Low BMI, Study Says
- Secondary Insurance Coverage Boosts Adherence to Treatment with Ofev, Esbriet, Study Finds
- Esbriet Safe and Effective for Patients with Advanced Idiopathic Pulmonary Fibrosis, Trial Suggests
- Algernon Plans to Test Its Lead Anti-fibrotic Compound in Animal Study of IPF
- Esbriet Extends Long-term Survival, Slows IPF Progression, Real-life Study Reveals
- Real-world Use of Esbriet and Ofev Supports Their Safety and Tolerability, Study Says
CPF News:
- Evel Knievel: Dedicated to Defying Death, Lost To IPF
- PFF Brings Daughters of PF Program Under Its Wings
- CPF Names 2014 Most Important Year for Pulmonary Fibrosis
- FDA Includes CPF Advocates in IPF Workshop
- CPF Organizing a Series of Educational Activities for the 2014 Pulmonary Fibrosis Awareness Month
- PFF and CPF Documentary About Idiopathic Pulmonary Fibrosis to Air on Discovery Channel
- Coalition for Pulmonary Fibrosis Group Leads National Pulmonary Fibrosis Month
IPF Clinical Trial News:
- 4 Factors that Impact Pulmonary Fibrosis Prevention
- Galecto’s Inhaled TD139 a Promising Therapy for IPF, Scottish Study Finds
- Bellerophon’s INOpulse Inhaled Nitrous Oxide Device Improves Symptoms of PH-IPF Patients, Study Finds
- Kadmon Presents Preclinical Data Supporting ROCK Inhibition as Way of Treating PF
- First Patient Enrolled in Trial of Ofev for Progressive Fibrosing Interstitial Lung Disease
- IPF Patients on Esbriet Live Approximately 2.5 Years Longer Than Untreated Patients, Study Finds
- Clinical Trial Shows TD139 as a Promising Therapy Against Pulmonary Fibrosis, Maker Says
FDA News:
- Plans for Phase 2 Trial of Brilaroxazine in IPF Patients Moving Ahead, Reviva Says
- PRM-151 Receives FDA Breakthrough Therapy Designation for IPF Treatment
- Saracatinib, Potential Oral IPF Therapy, Granted Orphan Drug Status by FDA
- FDA Clears Way for First Trials of IPF Treatment Candidate X-165
- Experimental IPF Therapy BBT-877 Gets FDA’s Orphan Drug Status
- Promedior’s Experimental IPF Therapy PRM-151 to Enter Phase 3 Stage
- Top 10 Pulmonary Fibrosis Stories of 2018